The effect of hormone therapy and tibolone on serum CD40L and ADAM-8 in healthy postmenopausal women
Irene Lambrinoudaki1, Maria Karaflou1, George Kaparos2, Odysseas Grigoriou1, Andreas Alexandrou3, Constantinos Panoulis1, Emanuel Logothetis2, Maria Creatsa1, George Christodoulakos1 & Evangelia Kouskouni2
Background/aim: The role of neutrophils and platelets in atherothrombotic disease is well established. The aim of our study was to investigate the effect of hormone therapy and tibolone on the soluble markers of neutrophil and platelet activation, ADAM-8 and CD40L respectively, in healthy postmenopausal women.
Subjects and methods: One hundred and six healthy postmenopausal women were randomly allocated to: estradiol plus drospirenone (E2/DSP), estradiol hemihydrate 1 mg plus norethisterone acetate (E2/NETA) 0.5 mg and tibolone 2.5 mg. Serum ADAM-8 and CD40L were measured at baseline and at 6 months.
Results: Baseline values of ADAM-8 and CD40L were similar between groups. No significant changes were observed between baseline values and values at 6 months.
Conclusions: No association has been revealed between estrogen plus progestin treatment or tibolone on serum ADAM-8 and CD40L levels in healthy postmenopausal women. Larger prospective studies are needed to further investigate the effect of low-dose hormone therapy or tibolone on serum markers of neutrophil and platelet activation.